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Abst ract
Pur pose: The purpose of this retrospective study was to 
evaluate the efficacy and safety of percutaneous transhe-
patic portal vein embolization (PVE) of the right liver lobe 
using Histoacryl/Lipiodol mixture to induce contralateral 
liver hypertrophy before right-sided (or extended right-
sided) hepatectomy in patients with primarily unresectable 
liver tumors. Methods: Twenty-one patients (9 females and 
12 males) underwent PVE due to an insufficient future liver 
remnant; 17 showed liver metastases and 4 suffered from 
biliary cancer. Imaging was performed prior to and 4 weeks 
after PVE. Surgery was scheduled for 1 week after a CT or MRI 
control. The primary study end point was technical success, 
defined as complete angiographical occlusion of the portal 
vein. The secondary study end point was evaluation of liver 
hypertrophy by CT and MRI volumetry and transfer to oper-
ability. Results: In all the patients, PVE could be performed 
with a Histoacryl/Lipiodol mixture (n = 20) or a Histoacryl/
Lipiodol mixture with microcoils (n = 1). No procedure-relat-
ed complications occurred. The volume of the left liver lobe 
increased significantly (p < 0.0001) by 28% from a mean of 
549 ml to 709 ml. Eighteen of twenty-one patients (85.7%) 
could be transferred to surgery, and the intended resection 
could be performed as planned in 13/18 (72.3%) patients. 
Conclusion: Preoperative right-sided PVE using a Histoacryl/
Lipiodol mixture is a safe technique and achieves a sufficient 
hypertrophy of the future liver remnant in the left liver lobe.
 Copyright © 2012 S. Karger AG, Basel
Intr oduction
Liver resection has been commonly assumed to be the 
gold standard treatment for advanced primary or second-
ary liver malignancies. It is the only curative therapeutic 
approach, but extensive resection of liver parenchyma in-
creases the risk of postoperative hepatic dysfunction up 
to hepatic failure [1–5].
Patients with normal liver parenchyma can tolerate a 
resection of 75% of the total liver volume without a sig-
nificant increase of postoperative hepatic failure, whereas 
in patients with underlying liver disease (e.g. liver cirrho-
sis or after chemotherapy) resections of 60–70% of the 
total liver volume were found to be safe [6–8]. In patients 
who would otherwise be good candidates for hepatic re-
section, the lack of adequate future liver remnant may be 
the only obstacle.
Hypertrophy of the left liver lobe occurs a few weeks 
after embolization of the right-sided portal veins, as a re-
sult of the regenerative capacity of the liver [9–12]. The 
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increase in remnant liver volume has been reported to be 
8–64% at various follow-up periods [9–11, 13–16]. The 
hypertrophy of the residual liver volume reduces the risk 
of postoperative organ failure and overall postoperative 
morbidity. Nowadays, portal vein embolization (PVE) 
is a widely used minimally invasive interventional pro-
cedure to improve the outcome of major liver resection 
and transfers initially unresectable patients into operable 
cases [11, 17].
Contraindications for PVE are portal vein thrombo-
sis, unresectable extrahepatic metastases and acute liver 
and renal failure.
Various different embolic agents (particles like polyvi-
nyl alcohol, absorbable gelatin sponges or microspheres, 
liquid embolic agents like absolute alcohol, thrombin or 
Ethibloc and metallic material like coils or the Amplatzer 
vascular plug) have been used for PVE. Our preferred 
embolic agent was Ethibloc (Ethicon, Germany), which 
is no longer available. On account of good experiences 
with Histoacryl in the preoperative embolization of renal 
carcinomas, we chose this material for PVE. The aim 
of this retrospective study was to evaluate the technical 
success of PVE of the right liver lobe with a Histoacryl/
Lipiodol mixture in patients with primarily unresectable 
liver tumors as primary study goal. The secondary study 
goal was the evaluation of contralateral liver hypertrophy 
by CT or MRI volumetry and the transfer to operability.
Materials and Methods
Patients
Between June 2007 and August 2010, 21 patients underwent 
percutaneous transhepatic right PVE at our institution prior 
to (extended) hemihepatectomy using a Histoacryl/Lipiodol 
combination. The indication for PVE was established indi-
vidually for each patient by radiological-surgical consensus. 
Preoperative PVE was indicated in patients with compromised 
liver function when the anticipated volume of future liver rem-
nant was <40% of the total liver volume, and <25% in patients 
with normal liver function.
Preprocedural and Postprocedural Imaging
In all patients, volumetry using CT or MRI was performed 
before and after PVE.
According to the study protocol, imaging was performed 
4 weeks after PVE in all patients. Surgery was then performed 
1 week after the CT control. Most of the patients were rou-
tinely examined by 64-row multidetector CT scan (Somatom 
Definition, Siemens, Erlangen, Germany) and 3-phase 
(nonenhanced, arterial and venous phase) CT images were 
obtained (fig. 1). After the nonenhanced phase, 120 ml iodin-
ated contrast medium (Ultravist-370 Bayer Vital; Leverkusen, 
Germany) was injected with an automated injector with a flow 
rate of 5 ml/s. The venous phase was started after a delay of 
40 s. The entire abdomen was scanned and axial and coronal 
reformations with 3-mm slice thickness were reconstructed 
and analyzed.
The images before the interventional procedure provided 
information regarding the number and location of the liver 
metastases/biliary cancers and the patency of all liver vessels 
as well as the resectability criteria, based on the evaluation of 
vascular relationships ensuring adequate perfusion.
After routine examination, the same protocol was used for 
the assessment of liver volume changes (fig. 2).
Patients with known allergic reactions after treatment with 
iodized contrast material or lack of availability were examined 
in external MRI before the interventional procedure.
All patients underwent measurement of total liver volume 
and volume of the right and left liver lobe both before and after 
PVE by CT or MRI volumetry. Total, right hemi and left hemi 
liver volumes were calculated before and after embolization 
with manual and semiautomated segmentation techniques of 
 Fig. 1. Contrast-enhanced CT (venous phase 3-mm slice) in a young female with rectal cancer. a Visualization 
of multiple liver metastases in the right liver lobe with a maximal diameter of 3 cm. b, c The extra- and intrahe-
patic portal vein can be delineated without thrombosis. 331 × 80 mm (300 × 300 DPI).
a b c
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the portal-phase images for volumetric calculations (Aquarius 
NET Viewer 4.4.4.23, TeraRecon Inc., Germany). A manual 
technique was used to outline the perimeter of the liver, ex-
cluding the gallbladder and the inferior vena cava on each sec-
tion, and the enclosed area was measured. Tumor volume was 
included in the calculations. The middle hepatic vein and the 
gallbladder were used as landmarks to define the border be-
tween the right and left liver lobes.
Material and Embolization Technique
PVE was performed as an inpatient procedure after moni-
tored analgosedation using intravenously administrated mid-
azolam (1.25 mg; Hoffmann La Roche, Germany) and 75 mg 
of pethidine (Aventis Pharma, Germany). In a standardized 
technique under CT guidance, the percutaneous puncture of the 
portal vein was performed with a 20-cm, 22-gauge Neff needle 
(Cook, USA) [12]. We have had good experiences with CT-
guided biopsies and punctures, so we did not use fluoroscopic 
or ultrasound-guided punctures. The next intervention was car-
ried out in the angiography suite. A 0.46-mm platinum wire was 
inserted via the needle into the portal vein retrogradely in order 
to position a 5-Fr introducer sheath. The wire and the introduc-
er sheath pusher were then removed once it had been observed 
that the sheath was positioned correctly in the portal vein.
After inserting a steerable 0.035-in stiff Terumo guidewire 
(Radiofocus, Terumo Japan), a 4-Fr Berenstein catheter was 
established in the main stem of the portal vein. The introduc-
er sheath was removed and a 4-Fr pigtail catheter was placed 
(Royal Flush Plus, Cook, USA) in the main stem of the portal 
vein for portography.
After analysis of the anatomy of the right-sided portal vein, 
a 4-Fr Vertebralis (Terumo Europe, Belgium) or Berenstein 
catheter was positioned in the posterior right-sided pedicle of 
the portal vein, and then a 2.7-Fr Progreat Terumo microcath-
eter (Terumo Europe) was put in the distal vessel and emboli-
zation was performed while pulling the catheter.
The target branches of the right portal vein were embolized 
with a mixture of Histoacryl/Lipiodol (Boston Scientific, USA/
Byk Gulden, Germany) (fig. 3).
Technical success was defined as the final occlusion of all 
vessels supplied by the portal vein excluding the proximal 2 cm 
of the feeding main portal. We excluded the proximal part of 
the feeding main portal to enable the surgeons to place a clamp 
without displacement of embolic material.
Statistics
All data were expressed as mean ± standard deviation (SD). 
A nonparametric matched-pairs test (the Wilcoxon signed-
rank test) was used to compare the volumetric data between the 
groups. Statistical analysis was performed using the GraphPad 
Prism package version 4.0c (GraphPad Software Inc., USA) 
with a p value of <0.05 indicating statistical significance.
Results
Patients
Twenty-one patients (9 females and 12 males) with a 
mean age of 61 ± 12.4 years (range 35–81 years) were in 
the study population. Of these, 17 had liver metastases, 
12 had colorectal cancer, 3 had a neuroendocrine pan-
creas tumor, 3 had gastrinoma, 1 had renal cancer and 4 
had biliary cancers [Klatskin tumors Bismuth IIIb (n = 1) 
and IV (n = 3)].
One patient (4.8%) with colorectal metastases had 
previously undergone percutaneous transarterial che-
moembolization of the right liver lobe, a second had had 
radiofrequency ablation of a metastatic lesion (also in the 
right liver lobe) and a third had had a surgical resection 
of liver segments 7 and 8. Eight patients (38.1%) with 
colorectal metastases had undergone chemotherapy and 
2 (9.5%) had undergone a combined radiochemptherapy. 
Liver fibrosis as an underlying liver disease, detected by 
preoperative biopsy, was seen in 2 patients (9.5%) as well 
as hepatitis B in 1 patient (4.8%).
Technical Success
The PVE procedures were technically successful in all 
of the patients. In 20 patients (95%) a contralateral CT-
guided approach was carried out and 1 patient (5%) an 
ipsilateral puncture, because of a small left hemi liver and 
Fig. 2. a Total occlusion of the right-sided 
portal venous system 30 days after embo-
lization with Histoacryl/Lipiodol. b The 
same patient 9 months after right-sided 
hemihepatectomy shows a massive hyper-
trophy of the residual liver. 212 × 80 mm 
(300 × 300 DPI). a b
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the absent of parenchymal coverage. The target branches 
of the right portal vein were embolized with a mixture of 
Histoacryl/Lipiodol alone with a mean ratio of 1:4 (de-
pendent on the end point; range 1:1–1:5) in 20 patients, 
and a combination of Histoacryl/Lipiodol with microcoils 
was used in 1 patient until complete occlusion of the right-
sided portal vein system was achieved. The mean volume 
of Histoacryl/Lipiodol was 6.6 ± 4.1 ml (range 2–15 ml). 
The fluoroscopy time was 17.1 ± 8.9 min (range 6.1–31.3 
min) on average, with a mean radiation dose of 194.6 ± 
127.7 Gy/cm2 (range 24–449 Gy/cm2).
Volumetry
The volume of the left liver lobe after embolization of 
the contralateral liver lobe at follow-up after 30 days (me-
dian) had significantly increased by a mean of 28% (+2.3 
to +70.0%) from a mean of 549 ml (296–1,029 ml) to 709 
ml (380–1,517 ml) (p < 0.0001) (table 1).
At the same time, there was an insignificant decrease 
in the volume of the right liver lobe by a mean of 4.4% 
(–23.1 to –28.2%) after embolization from a mean of 
1,205 ml (817–2,186 ml) to a mean of 1,130 ml (628–
1,816 ml) (p = 0.0551). There was not a significant in-
crease (mean 5.1%; –13.3 to +26.3) in the total volume of 
the liver from a mean of 1,754 ml (1,216–2,697 ml) to a 
mean of 1,830 ml (1,293–2,849 ml) (p = 0.1840).
The ratio of residual liver/total liver volume increased 
by a mean of 23.3% (–7.4–61.1%) from a mean of 31.6% 
(18–45%) to a mean of 38.4% (22–55%). After PVE, 
complete occlusion of the portal veins was achieved in 
Fig. 3. a Placement of a pigtail catheter in the main portal branch after CT-guided puncture of the left portal 
vein. b Catheterization of a right-sided portal branch via a microcatheter system. c, d Visualization of the entire 
embolized area of the right-sided portal branches. 228 × 160 mm (300 × 300 DPI).
a b
c d
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all patients with no detection of portal venous recanali-
zation in the CT after a median of 30 ± 25.1 days (range 
16–132 days).
Complications and Postinterventional Follow-Up
No embolization-related acute liver failure occurred. 
No patient experienced puncture-site complications, 
such as hematoma, portal vein thrombosis, infections, 
cholangitis or pneumothorax.
One patient (4.8%) developed fever within 24 h of the 
embolization procedure and 2 (9.5%) exhibited persis-
tent abdominal pain. All patients were discharged from 
the hospital after a median of 3.0 ± 0.8 days after emboli-
zation (range 2–5 days).
Surgery/Liver Resection
Out of 21 patients, 18 (85.7%) underwent surgery 
a median of 36.0 ± 16.8 days (range 21–89) after PVE. 
Hemihepatectomy was feasible in 13 of these 18 (72.3%); 
this included an extended right-sided hemihepatectomy 
in 6 (46.2%) and a right-sided hemihepatectomy in 7 
(53.8%). R0 resection was achieved in 9 patients (69.2%), 
R1 in 3 (23.1%) and R2 in just 1 (7.7%).
Five patients (23.8%) underwent an exploratory lapa-
rotomy only, due to intraoperative findings [irresectable 
tumor/intrahepatic metastases (n = 3) or peritoneal car-
cinomatosis (n = 2)]. Three patients (14.3%) did not even 
undergo an exploratory laparotomy because of insuffi-
cient hypertrophy of the left liver lobe and/or progressive 
metastases 33 days (range 28–41 days) after PVE.
Three patients (16.7%) suffered from perihepatic ab-
scesses after surgery. Unfortunately, 2 patients (11.2%) 
died after extended right-sided hemihepatectomy due 
to liver failure and other complications (e.g. respiratory 
failure). No transient liver failure occurred after surgery.
Following surgery, patients were discharged after a 
median of 15.0 ± 19.6 days (range 8–77 days).
In 2 patients with insufficient hypertrophy, 39 and 46 
days after PVE, respectively, an Amplatzer vascular plug 
(AGA Medical, Germany) was placed over a transjugu-
lar approach into the right hepatic vein to occlude it and 
to induce further hypertrophy of the left liver. In one of 
these 2 patients, after technically successful PVE but with 
insufficient hypertrophy even after the placement of the 
Amplatzer device, no operation was feasible due to in-
sufficient hypertrophy of the left liver lobe and the oc-
currence of new metastases in the future liver remnant. 
The second patient showed sufficient hypertrophy and 
was transferred to surgery; however, a surgical resection 
proved not feasible due to the intraoperative detection of 
distant peritoneal metastases.
Discussion
Percutaneous transhepatic PVE is an established strat-
egy to reduce the risk of liver dysfunction or failure after 
(extended) hemihepatectomy. First described in humans 
in the early 1980s, this procedure has become a widely 
accepted preoperative method in an effort to increase the 
number of operable patients among those who are can-
didates for hepatic resection [11, 15]. The occlusion of 
portal branches comprises a 2-fold effect: atrophy of the 
embolized parenchyma and hypertrophy of the unembo-
lized parenchyma. Previous study findings have suggest-
ed that 40% of the total liver volume must be preserved 
in patients with a liver that has been damaged by chemo-
therapy or underlying liver diseases e.g. liver cirrhosis. 
The hypertrophy rate of the unembolized liver segments 
is variable and depends on the underlying liver disease 
and systemic diseases [3].
Various embolic agents have been used for the pre-
operative PVE of liver metastases or malignant liver 
tumors and there is still a debate regarding the optimal 
embolic material [18–20]. Because our previous pre-
ferred embolic agent Ethibloc was no longer available, 
we chose Histocryl as a replacement, because of many 
years of experience with the use of a Histoacryl/Lipiodol 
combination in the preoperative embolization of renal 
carcinomas.
Similar to Ethibloc, Histoacryl is used in a mixture 
with Lipiodol and leads to total and permanent occlu-
Table 1. Relative liver volumes before and after PVE
Left liver lobe volume 
before PVE (ml) 
Left liver lobe volume 
after PVE (ml) 
Hypertrophy 
ratio left lobe 
(%)
Total liver volume 
before PVE (ml) 
Total liver volume 
after PVE (ml) 
Increase in left 
lobe/ total liver 
volume (%) 
549.4 (296–1,029) 708.6 (380–1,029) 28 (2.3–70) 1,754 (1,216–2,697) 1,830 (1,293–2,849) 23.27 (–7.4–61.1)
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sion of the embolized area, as has been demonstrated 
by follow-up CT scans. Furthermore, Lipiodol is used 
to control the precipitation; with a mixture of 1:4, we 
can achieve a deep capillary embolization without risk-
ing recanalization. Other advantage of Histoacryl are its 
syringeability through a microcatheter in combination 
with glucose and being able to use it independently ac-
cording to the clotting situation.
A disadvantage is the difficult application with the risk 
of failed embolization. Early polymerization with the risk 
of occlusion of the microcatheter must also be discussed.
Liver Hypertrophy after PVE
There are variable data about the increase of the re-
sidual liver parenchyma volume ranging from 13 to 127% 
[21, 22] (table 2). This variability can be explained by the 
use of different embolic agents, varying intervals between 
the embolization and the operation and/or varying stages 
of liver function before an intervention.
In this study, we observed a significant increase of 
28% (from mean of 549 to 709 ml) in the volume of the 
left liver lobe after PVE, which is comparable to one of 
our previous studies that showed an increase of 28.3% 
with our standard Ethibloc/Lipiodol mixture [12].
Finally, we were able to transfer 18/21 (85.7%) pa-
tients into operability. The planned operation was fea-
sible in 13/18 (72.3%) patients, which was equivalent to 
our previous study where it had proved feasible in 11/13 
(81.8%) patients.
The use of Amplatzer vascular plugs showed a satis-
fying result only in 1 of 2 patients. A second study with 
a larger study population would be required to evaluate 
the efficacy in achieving an additive hypertrophy of the 
contralateral liver lobe using these plugs. Yamanaka et 
al. [23] reported that the regeneration process of nor-
mal liver parenchyma after surgical resection occurs in 3 
phases: a rapid increase was seen during the first month, 
a decrease during the second month and finally a slow 
increase. This variability in the increase of volume could 
be due to the varying intervals between PVE and surgery 
as well as different embolic agents and varying preinter-
ventional stages of liver disease and function.
The complication rate found in recent literature lies 
between 9 and 15%, including pneumothorax, subcap-
sular hematoma, pseudoaneurysm, hemobilia and portal 
vein thrombosis [24, 25]. We found no procedure-related 
complications in our study.
Moderate symptoms of postembolization syndrome, 
i.e. fever, nausea, leukocytosis and elevated values of CRP 
were present in most of the patients.
The limitations of this study are its retrospective na-
ture and the small study population. A larger prospective 
study with a longer follow-up period is needed to con-
firm our findings.
Conclusion
Preoperative PVE with Histoacryl/Lipiodol mixture is 
a safe and successful method resulting in compensatory 
hypertrophy of the unembolized liver.
Table 2. Overview of the current literature
Authors Year Embolization 
material
Number
of
patients
Compli-
cations
Liver metastases/
HCC/CCC
Hypertrophy 
residual liver
Increase in 
ratio: residual 
liver lobe/
total liver 
volume
Madoff [3] 2003 PVA/coils 26 07.7% Liver metastases/HCC/CCC 08.0% 41.1%
Covey AJR 2005 PVA 58 00% Liver metastases 24.3–31.9%  9–10.0%
Radeleff [12] 2008 Ethibloc/Lipiodol 14 14.3% Liver metastases/HCC/CCC 28.3% 27.1%
Our study 2010 Histoacryl/Lipiodol 21 00% Liver metastases /CCC 28.0% 23.3%
CCC = Cholangiocellular carcinoma; HCC = hepatocellular carcinoma; PVA = polyvinyl alcohol.
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